Presentations and discussions from UK CAR T-cell specialists
The CAR3: Study Day for Haematology Nurses took place virtually on 25 September. Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the hematological oncology field. But despite their benefits, CAR T-cell therapies come with high risk for serious adverse events. Nurses play a critical role in monitoring and managing adverse events related to CAR-T therapy. Additionally, oncology nurses are crucial in educating patients and caregivers on CAR T-cell therapy.
Therefore, it is essential to educate nurses to maintain their knowledge and skills in a complex and evolving setting and deliver safe, quality patient care. At the meeting, presentation topics included the science of CAR T-cells, UK patient data, ITU and the ward as well as palliative care for CAR-T patients. The role of pharmacy, CAR-T toxicities and psychological support of patients were also discussed. Watch the full series of presentations from the meeting below.
UK patient data
Andrea Kuhnl King’s College Hospital, London, United Kingdom
Bridging the gap between ITU and the ward
Tasneem Pirani King's College Hospital, London, United Kingdom
Ruth Ting King’s College Hospital, London, United Kingdom
Patient profiles and success stories
Maria Mazza-Beange Bristol Haematology Oncology Centre, Bristol, United Kingdom
The role of pharmacy in CAR-T cells
Alice Mason Royal Marsden Hospital, London, United Kingdom
Emma Smith & Órla Stewart, King’s College Hospital, London
Final discussion & closing remarks
Chairs: Órla Stewart, King’s College Hospital, London & Rose Ellard, Royal Marsden Hospital, London